Combination therapy with cagrilintide and semaglutide vs cagrilintide alone, semaglutide alone, and placebo is superior for improving weight loss results.

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

Novo Nordisk A/S (NYSE: NVO) has announced headline results from a Phase 2 trial of CagriSema, a once-weekly subcutaneous combination of semaglutide and amylin analog cagrilintide. In the trial ...

CagriSema patients lost more weight than those taking either component alone: 20.4% for the combination vs 11.5% with cagrilintide, 14.9% with semaglutide, and 3% with placebo. About half of those ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.

The CagriSema (2.4 mg semaglutide and 2.4 mg cagrilintide) phase 3 programme in people with overweight and obesity, REDEFINE, is expected to begin in the fourth quarter of 2022.

Novo Nordisk presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP ...

Semaglutide, or Ozempic, reduces symptoms of feared diabetes’ complication, study finds Kelly Grant Health reporter Published March 29, 2025 Updated March 30, 2025 ...

At week 68, participants in REDEFINE 1 had lost a mean 20.4% of their body weight with CagriSema vs 14.9% with semaglutide, 11.5% with cagrilintide, and 3.0% with placebo.